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Abstract
Background: The survival of patients with ovarian cancer has improved because of surgery and chemotherapy.
This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the
introduction of targeted therapy for ovarian cancer.
Methods: Data were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with
epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using
the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and
clinicopathological factors with ovarian cancer survival.
Results: During the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative
survival rate improved from 57.2% during 1995–1999 to 63.8% during 2010–2014 (P < 0.001). Survival outcomes
improved between 1995 and 1999 and 2010–2014 for the serous and endometrioid carcinoma subtypes (P < 0.001).
However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P = 0.189 and
P = 0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary
surgical treatment, and non-serous histological subtype were favorable prognostic factors.
Conclusion: Survival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last
20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.
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Background
Ovarian cancer is the most common cause of gynecological
cancer-related death in Korea, and causes approximately
1021 deaths annually [1]. The incidence and mortality
of ovarian cancer have increased continuously, and
2413 new cases were detected in 2014 [1–3].
Approximately 75% of the newly diagnosed patients
have advanced-stage disease, which partly explains the
high mortality rate for this cancer [4, 5].
During the last 20 years, there has been an improve-
ment in survival of patients with ovarian cancer [1, 4–6].
A number of strategies have been evaluated with the
goal of improving survival, and some of these strategies
have become standard treatments for ovarian cancer.
For example, debulking surgery has been emphasized
because optimal cytoreduction is one of the most signifi-
cant predictors of survival [7], and previous studies have
revealed that optimal surgical cytoreduction improves
survival in cases of advanced-stage disease [8]. In
addition, paclitaxel plus cisplatin has been introduced as a
front-line therapy for ovarian cancer, and provides better
survival outcomes than cyclophosphamide-based regimens
[9]. After then, platinum-based chemotherapy has been im-
proved with less toxic and equivalent analogs, carboplatin
[10, 11], and paclitaxel plus carboplatin is the most com-
monly used first-line therapy for ovarian cancer. Moreover,
better survival rates have been observed in patients with re-
current disease, with a number of chemotherapies having
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activity even in platinum-resistant settings. Although
recent phase III trials have supported the introduction
of targeted agents [12–14], their economic cost, lim-
ited insurance coverage, and low patient preference
have limited the use of these agents in routine clinical
practice [15, 16]. In Korea, the addition of bevacizu-
mab to standard chemotherapy was approved in 2013,
and the national insurer only began covering the cost
of bevacizumab for platinum-resistant recurrent ovar-
ian cancer in August 2015. Therefore, the present
study aimed to investigate the changes in the survival
rates among Korean patients with ovarian cancer dur-
ing the last 20 years, and to identify unmet clinical
needs that might be targeted to improve outcomes.
Methods
This study utilized data from the Korean National Cancer
Incidence Database (KNCIDB), which includes data from
the Korea Central Cancer Registry (KCCR) and information
regarding patients’ demographic characteristics, primary
cancer site, morphology, diagnosis date, and initial treat-
ment. KCCR was launched as a nationwide hospital-based
cancer registry in 1980 by the Ministry of Health and
Welfare, and subsequently expanded to cover the entire
population in 1999. The present study evaluated survival
data from the KNCIDB. The ovary cancer cases were classi-
fied according to the International Classification of Diseases
for Oncology, 3rd edition [17] and converted according to
the International Statistical Classification of Diseases and
Related Health Problems, 10th edition (ICD-10: C-56) [18].
We included only cases of epithelial ovarian cancer,
diagnosed between 1995 and 2014. All cases of
non-epithelial ovarian cancer (e.g. sex-cord stromal tumors
and germ cell tumors) were excluded. All cases followed
until 31 December 2015.
The present study’s retrospective design was approved
by the institutional review board of the National Cancer
Center (NCC2017–0168).
Age at the diagnosis was classified as < 40 years old,
40–59 years old, and > 59 years old. Histological sub-
types were categorized as serous carcinoma, mucinous
carcinoma, endometrioid carcinoma, clear cell carcin-
oma, and others. Staging information was based on the
Surveillance, Epidemiology, and End Results (SEER)
summary staging [19], which categorizes cancer spread
from its origin (localized, regional, and distant), because
the KCCR has collected this information since 2005.
Primary treatments within 4 months were categorized as
surgery, chemotherapy, and others.
For the survival analyses, we obtained the data from
KNCIDB and the mortality data from Statistics Korea.
Relative survival is the ratio of the observed survival rate
among patients with cancer, compared to the expected
survival rate among age- and sex-matched individuals
from the general population. We calculated the relative
survival rates (RSRs) using the Ederer II method [20].
Furthermore, we divided the patients into 5-year cohorts
based on their diagnosis date to evaluate their 5-year
RSRs (1995–1999, 2000–2004, 2005–2009, and 2010–
2014). The Cox regression proportional hazard model
adjusted to estimate hazard ratio (HR) for the age at
diagnosis, SEER stage, year of diagnosis, primary
treatment (with or without surgery), and histological
subtype [21]. The proportionality of hazards assump-
tion over time was tested for each factor [22]. All
analyses were performed using SAS software (version
9.3; SAS Institute, Cary, NC, USA).
Results
A total of 22,880 women were diagnosed with ovarian can-
cer between 1995 and 2014, and their characteristics are
shown in Table 1. The overall 5-year RSR significantly im-
proved during study period (57.2% during 1995–1999,
60.2% during 2000–2004, 59.4% during 2005–2009, 63.8%
during 2010–2014; P for trend < 0.001) (Fig. 1). Figure 2
shows the survival outcomes according to histological sub-
type, which improved for the serous and endometrioid car-
cinoma subtypes between 1995 and 1999 and 2010–2014
(P for trend < 0.001). However, no significant improvements
were observed for the mucinous and clear cell carcinoma
subtypes (P for trend = 0.189 and 0.293, respectively).
Table 2 shows the 5-year RSRs of patients with ovarian
cancer according to histological subtype and SEER stage.
The overall 5-year RSRs improved from 59.4% during
2005–2009 to 63.8% during 2010–2014 (P < 0.001).
Improved survivals were also observed for early-stage ser-
ous carcinoma (from 77.7% during 2005–2009 to 84.1%
during 2010–2014). Furthermore, there was a significant
increase in the 5-year RSR for advanced-stage serous car-
cinoma, from 44.1% during 2005–2009 to 49.5% during
2010–2014. However, women with non-serous carcinoma
subtypes did not experience a survival improvement, with
the exception of women with early-stage endometrioid
carcinoma.
Table 3 shows the results for the age-based changes in
the 5-year RSRs. During 2005–2009 and 2010–2014,
patients who were 40–59 years old and > 59 years old
experienced an increased 5-year survival rate, although
younger patients did not experience a survival improve-
ment, regardless of their cancer stage. Patients who
underwent surgery had a significantly higher 5-year RSR,
compared to patients who did not undergo surgery, and
this association strengthened over time.
In the Cox multivariate model, the significant prog-
nostic factors were age at diagnosis, SEER stage, primary
treatment, and histological subtype. Furthermore, year of
diagnosis was an independent prognostic factor, with pa-
tients who were diagnosed during 2010–2014 being 27%
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less likely to die, compared to patients who were diag-
nosed during 1995–1999 (hazard ratio: 0.73; 95% confi-
dence interval: 0.65–0.81) (Table 4).
Discussion
Between 1995 and 2014, there has been a gradual in-
crease in the survival of Korean patients with ovarian
cancer. Among women with serous carcinoma, the
risk of death from ovarian cancer during 2010–2014
was 4.7% lower, compared to during 2005–2009, and 8.5%
lower compared to during 1995–1999. Improvement of
survival was found for both early stage and distant
stage. However, no improvements were observed for
patients with the mucinous and clear cell carcinoma
subtypes.
The current approach to managing ovarian cancer in-
volves cytoreductive surgery followed by chemotherapy,
and a decrease in the proportion of patients without de-
finitive treatment has been observed during the last
20 years (from 12.2% during 1995–1999 to 6.0% during
2010–2014). Thus, an increasing number of Korean pa-
tients have benefited from surgery and chemotherapy,
and adherence to the standard treatment guidelines is an
independent predictor of improved survival [23, 24].
Furthermore, in the present study, the multivariate ana-
lysis revealed that surgery was independently associated
with better outcomes.
The use of platinum-based chemotherapy has im-
proved with the development of less toxic analogs (car-
boplatin), as well as research regarding the optimal dose,
schedule, sequence, and duration of treatment. In this
Table 1 Basic characteristics according to the time period of ovarian cancer diagnosis
Total 1995–1999 2000–2004 2005–2009 2010–2014
(n = 22,880) (n = 3740) (n = 4863) (n = 6317) (n = 7960)
No. of cases % p-value No. of cases % No. of cases % No. of cases % No. of cases % p-value
Age (years) <.0001 <.0001
< 40 3849 16.8 945 25.3 910 18.7 990 15.7 1004 12.6
40–59 12,169 53.2 1813 48.5 2526 51.9 3378 53.5 4452 55.9
> 59 6862 30.0 982 26.3 1427 29.3 1949 30.9 2504 31.5
SEER Stage <.0001 <.0001
Localized 3865 16.9 – – – – 1683 26.6 2182 27.4
Regional 2564 11.2 – – – – 1053 16.7 1511 19.0
Distant 6795 29.7 – – – – 2843 45.0 3952 49.6
Unspecified 9656 42.2 – – – – 738 11.7 315 4.0
Primary treatment <.0001 <.0001
Surgery only 6007 26.3 1213 32.4 1252 25.7 1626 25.7 1916 24.1
Chemotherapy only 1680 7.3 326 8.7 371 7.6 414 6.6 569 7.1
Surgery + Chemotherapy 13,262 58.0 1745 46.7 2713 55.8 3805 60.2 4999 62.8
Others 1931 8.4 456 12.2 527 10.8 472 7.5 476 6.0
Histology <.0001 <.0001
Serous carcinoma 10,837 47.4 1459 39.0 2119 43.6 3186 50.4 4073 51.2
Mucinous carcinoma 4005 17.5 916 24.5 1027 21.1 951 15.1 1111 14.0
Endometrioid carcinoma 2191 9.6 399 10.7 494 10.2 580 9.2 718 9.0
Clear cell carcinoma 1923 8.4 164 4.4 327 6.7 551 8.7 881 11.1
Others 3924 17.2 802 21.4 896 18.4 1049 16.6 1177 14.8
SEER Surveillance, Epidemiology, and End Results
Fig. 1 Relative survival rate of ovary cancer by time period
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context, the Gynecologic Oncology Group (GOG) 0111
and OV10 studies revealed that cisplatin plus paclitaxel
was superior to cisplatin plus cyclophosphamide [9, 25].
In addition, the GOG 0158 and Arbeitsgemeinschaft
Gynäkologische Onkologie Ovarian Cancer Study Group
(AGO-OVAR) studies demonstrated that carboplatin
Fig. 2 Trends in relative survival rate according to histology and the time period (a) serous carcinoma (b) mucinous carcinoma (c) endometrioid
carcinoma (d) clear cell carcinoma
Table 2 Five-year relative survival rate, by SEER stage and
histologic subtype
2005–2009
(n = 6317)
2010–2014
(n = 7960)
p-value
Early stagea 81.5 86.3 <.0001
Serous carcinoma 77.7 84.1 <.0001
Mucinous carcinoma 87.6 88.6 0.379
Endometrioid carcinoma 88.5 93.6 0.047
Clear cell carcinoma 86.4 87.4 0.673
Distant stage 38.7 43.9 <.0001
Serous carcinoma 44.1 49.5 <.0001
Mucinous carcinoma 30.2 31.5 0.247
Endometrioid carcinoma 50.3 60.1 0.752
Clear cell carcinoma 38.0 22.5 0.012
SEER Surveillance, Epidemiology, and End Results
aEarly stage: local + regional
Table 3 Five-year relative survival rate, by age and primary
treatment
2005–2009
(n = 6317)
2010–2014
(n = 7960)
p-value
Age
Early stagea 81.5 86.3 <.0001
< 40 89.1 91.6 0.203
40–59 83.9 88.1 <.0001
> 59 66.8 77.0 0.001
Distant stage 38.7 43.9 <.0001
< 40 46.2 44.7 0.808
40–59 44.9 50.5 <.0001
> 59 28.2 34.1 0.002
Surgery
Early stagea 81.5 86.3 <.0001
with surgery 82.6 87.1 <.0001
without surgery 62.3 60.7 0.383
Distant stage 38.7 43.9 <.0001
with surgery 42.5 47.6 <.0001
without surgery 24.0 27.2 0.413
aEarly stage: local + regional
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plus paclitaxel was not inferior to cisplatin plus pacli-
taxel [10, 11]. Thus, the incorporation of paclitaxel into
first-line therapy has improved the ovarian cancer sur-
vival rate. This change was adopted by Korean gyneco-
logic oncologists during 2000–2004, and may partially
explain the improvement in survival between 1995 and
1999 and 2010–2014.
However, after the incorporation of paclitaxel into
first-line chemotherapy, the first-line chemotherapy
options have not substantially changed during the last
decade. Although a randomized phase III trial re-
vealed a survival benefit after treatment using intra-
peritoneal chemotherapy [26], this procedure has not
been widely accepted in Korea. The Japanese Gynecologic
Oncology Group (JGOG) 3016 study also revealed the su-
periority of dose-dense weekly paclitaxel plus carboplatin,
compared to the standard dosing of paclitaxel [27], al-
though this approach also has limited acceptance in
Korea.
Previous studies have emphasized the importance of
debulking surgery for ovarian cancer. Bristow et al.
found that maximal cytoreduction was one of the
most powerful determinants of survival among
patients with advanced disease during the platinum
era [8]. Thus, many Korean gynecologic oncologists
adopted radical surgery and a multidisciplinary
approach that includes general surgeons, thoracic
surgeons, and urologists. This approach might also
explain the improvement in survival between 2005
and 2009 and 2010–2014, and could highlight the im-
portance of surgery in the era of chemotherapy using
paclitaxel plus carboplatin.
Furthermore, advances in chemotherapy for the recur-
rent and supportive care settings might help improve
survival outcomes [6]. During the next decades,
enormous changes in survival are expected based on the
incorporation of targeted treatments for ovarian cancer.
For example, the combination of bevacizumab plus
paclitaxel and carboplatin provides a survival benefit in
patients with advanced-stage ovarian cancer. In addition,
the GOG 218 and International Collaboration on
Ovarian Neoplasms trial 7 (ICON 7) studies revealed a
progression-free survival benefit in the first-line setting
[13, 28], while three randomized phase III trials revealed
a survival benefit the recurrent setting [12, 14, 29].
Moreover, mature data from phase II and III trials with
PARP inhibitors will be available in the next few years,
and Study 19 has already revealed a remarkable survival
benefit after olaparib treatment for patients with a BRCA
mutation and platinum-sensitive recurrence [30]. Based on
Table 4 Estimated hazard ratio of ovarian cancer prior to the era of targeted therapy
N No. of deaths Adjusted HRb 95% CI p-value
Age (years)
< 40 3849 988 ref. ref. –
40–59 12,169 4992 1.71 (1.60–1.84) <.0001
> 59 6862 4328 3.00 (2.79–3.22) <.0001
SEER Stage
Early stagea 6429 1113 ref. ref. –
Distant stage 6795 3777 3.23 (3.02–3.46) <.0001
Year of diagnosis
1995–1999 3740 2230 ref. ref. –
2000–2004 4863 2671 0.89 (0.84–0.95) 0.000
2005–2009 6317 3227 0.94 (0.85–1.03) 0.185
2010–2014 7960 2180 0.73 (0.65–0.81) <.0001
Primary treatment
With surgery 19,776 8122 ref. ref. –
Without surgery 1772 1233 1.49 (1.39–1.58) <.0001
Histology
Serous carcinoma 10,837 5325 ref. ref. –
Mucinous carcinoma 4005 1226 0.71 (0.67–0.76) <.0001
Endometrioid carcinoma 2191 670 0.69 (0.63–0.75) <.0001
Clear cell carcinoma 1923 507 0.80 (0.73–0.88) <.0001
Others 3924 2580 1.49 (1.42–1.57) <.0001
aEarly stage: local + regional, HR, hazard ratio; ref., reference; CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results
badjusted for Age, SEER stage, Year of Diagnosis, Primary treatment and Histology
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these results, the Korean Food and Drug Administration
approved bevacizumab in 2013 and olaparib in 2016.
Nevertheless, targeted drugs were rarely used during the
present study’s period, and only a few patients would have
received targeted drugs in clinical trials.
Despite the progress in treating serous carcinoma dur-
ing the last 20 years, we did not observe any survival im-
provements for the mucinous and clear cell carcinoma
subtypes. Although epithelial ovarian cancer has signifi-
cant heterogeneity and the histological subtype is a
well-known prognostic factor, the current management
strategies do not consider the histological subtype.
Previous studies have confirmed that patients with mu-
cinous tumors have inferior long-term survival, com-
pared to the serous or endometrioid subtypes, which is
related to a poor response to platinum-based chemo-
therapy [31, 32]. However, advances in the pathological
diagnosis of ovarian mucinous carcinoma have allowed
pathologists to distinguish between primary and meta-
static mucinous carcinoma, which has led pathologist to
suggest that primary ovarian mucinous tumors are rare
[33]. The GOG 241 study aimed to compare the efficacy
of carboplatin plus paclitaxel +/− bevacizumab to that of
oxaliplatin plus capecitabine +/− bevacizumab as
first-line chemotherapy for patients with mucinous
adenocarcinoma, although there has been limited enroll-
ment in that study because of this subtype’s rarity.
The incidence of clear cell carcinoma has increased
markedly in Korea across all age groups since 1999 [2].
Previous reports have confirmed that women with endo-
metriosis have an elevated risk of developing clear cell
carcinoma, and this trend is expected to continue in the
near future, based on the increasing incidence of endo-
metriosis in Korea [34, 35]. The JGOG 3017 study com-
pared the efficacy of irinotecan plus cisplatin versus
paclitaxel plus carboplatin as a first-line chemotherapy
[36], although no subtype-specific survival benefits were
observed for the irinotecan plus cisplatin regimen. Chan
et al. did not report any change in survival rates for pa-
tients with clear cell carcinoma after analyzing the data
available on the Surveillance Epidemiology and End Re-
sults Database [4]. Therefore, treatment using existing
anticancer agents has limited ability to improve the
prognosis of patients with clear cell carcinoma. The
present study also revealed poor survival outcomes and
no improvement in the outcomes for advanced-stage
clear carcinoma.
The present study is one of the largest population-based
studies to evaluate the survival rate of ovarian cancer
using available histological and cancer stage data.
Although the present study’s findings are strengthened by
the large nationally representative sample of Korean
women, there are also several limitations. First, the KCCR
database does not include disease information such as
International Federation of Gynecology and Obstetrics
(FIGO) staging and survival information such as re-
currence and the cause of death. Hence, we could not
identify the specific cause of death for each case. In
addition, the sociodemographic information such as
region, residence and hospital cannot be obtained
from the KCCR database for research purpose. There-
fore, we could not analyze the data obtained for the
indicators related to the health system. Second, there
is no detailed information regarding the surgery and
chemotherapy, such as surgeon specialty, extent of
debulking, residual disease, neoadjuvant or postopera-
tive chemotherapy, and the specific regimens. Thus,
as we observed an improved survival rate among pa-
tients who underwent surgery, it is possible that this
finding was biased by the selection of healthier pa-
tients in the surgery group. Third, central pathology
reviews are not performed for patients who are regis-
tered in the KCCR.
Conclusion
Ovarian cancer survival has improved in Korea during the
last 20 years. However, no improvements were observed
for the mucinous and clear cell carcinoma subtypes. Given
the low survival rate in cases with advanced-stage mucin-
ous/clear cell subtypes, clinical trials with novel treatment
strategies are urgently needed to improve clinical out-
comes in these cases.
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